ClinicalTrials.gg
Status unknownNCT03297268BESIUpdated Sep 29, 2017

Behavioral and Environmental Sensing and Intervention

An observational study in Behavioral and Psychiatric Symptoms of Dementia, Dementia and Caregivers, sponsored by University of Virginia. Status unknown at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2017-09-29.

Sponsored by University of Virginia · Observational

The sponsor has not verified this record recently (last verified Sep 2017), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Family-based
Time perspective
Cross-sectional
Enrollment
24
Ages
50 Years and older
Sex
All
01

Study summary

This 3-phase research plan to employ Behavioral and Environmental Sensing and Intervention (BESI) will overcome the fundamental scientific barriers to realizing prediction of agitation episodes and detection early stages of dementia related agitation. The goal of which is empowering caregivers to intervene early and ultimately reduce agitation, thus reducing caregiver burden and extending aging-in-place and improving the associated quality-of-life and cost benefits.

Read the detailed description

The dementia syndrome of Alzheimer's disease and other disorders is rapidly expanding due to the aging of society and the longevity of citizens. In its varying stages, care of the dementia syndrome requires differing sets of skills from the caregivers, and more skilled intervention is required as the disease progresses. These caregivers experience increased burden due to the challenges and stresses of caring. A recent systematic review of caregiver burden factors revealed dementia-related agitation to be the most prevalent factor leading caregivers to institutionalize community-dwelling loved ones with dementia. Tools that empower caregivers to proactively reduce the incidents and severity of agitation would reduce stress and increase self-efficacy, thereby extending aging-in-place and the associated quality-of-life and cost benefits.

This project proposes to develop, deploy, and evaluate such a tool and to address the fundamental scientific challenges to realizing the benefits of such a technology to caregivers and persons with dementia (PWD). The tool - BESI: Behavioral and Environmental Sensing and Intervention - will be an empowerment tool for caregivers of community-dwelling PWD. BESI comprises:

  1. a system of body-worn inertial sensors and in-home acoustic, light, temperature, and motion sensors,
  2. data analysis techniques to detect and assess agitation and environmental context from these sensor streams,
  3. models for the relationship between agitation and the environment that are trained for each PWD-caregiver dyad based on a\&b, and
  4. automated real-time notifications to the caregiver based on b\&c (e.g., detection of early agitation stages or of an environment (cumulative and/or instantaneous based on the models) that has led to agitation in the past), empowering the caregiver to intervene before agitation escalation.
02

Conditions studied

  • Behavioral and Psychiatric Symptoms of Dementia
  • Dementia
  • Caregivers

Keywords

  • Dementia Caregiver Empowerment
  • Caregiver Burden
  • Agitation in Dementia
  • Environmental Sensors
  • Wearable Technology
03

In context

Behavior

1,573 studies on the registry are indexed under Behavior; 313 are open to participants now.

This study's planned enrollment of 24 is below the median of 235 across 341 observational studies indexed under Behavior.

Browse Behavior studies →

Lead sponsor

University of Virginia is the lead sponsor of 675 studies on the registry; 138 are open to participants now.

Of its 61 completed or terminated interventional studies of FDA-regulated products, 42 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Community sample of people with dementia living at home with unpaid caregivers.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of dementia
  • Living in one home for at least 2 months without hospitalization
  • Caregiver seeking support for caregiving needs
  • Have a stable caregiver
  • Be able to provide consent or assent

Exclusion criteria

Exclusion Criteria:

  • Hospitalization in the last 2 months
  • Multiple and inconsistent caregivers
  • Living in multiple homes
  • Unable to provide consent or assent
  • No known dementia
05

Study design

Observational model
Family-based
Time perspective
Cross-sectional
Enrollment
24 participants (estimated)
Patient registry
No

Groups and cohorts

  • Phase 1-Controlled Validation & Study Planning

    Phase 1 is focused on refining and ultimately verifying BESI's basic sensing and notification functionality and validating BESI's environmental assessments in a controlled setting - namely the laboratory and homes of two healthy volunteers. This phase also serves to support further requirements gathering to refine BESI for community-based deployment. No interventions are delivered.

  • Phase 2 - In-situ Validation and Ethnographic Analysis

    Phase 2 starts the deployment of the technology within a community context, with the goals of validating the system's ability to assess agitation and environmental events in-situ and developing the cyber-sociophysical system models based on the dyad-specific relationship between agitation and the environment. A hybrid remote ethnographic methodology will be used, combining remote BESI measurement and caregiver diaries and a time-series design for the administration of the assessment battery.

  • Phase 3 - Intervention with Home-Based Caregivers

    Phase 3 is the intervention phase and the full realization of BESI. The goal is to employ the validated assessment capabilities and the developed modeling techniques to enable real-time, dyad-specific caregiver notifications that empower a caregiver to intervene with the PWD and/or environment before agitation escalation. In addition to validation of the BESI's ability to provide such appropriate notifications, Phase 3 will also serve as a pilot study about the effect that these notifications have on caregiver empowerment (as measured by self-efficacy) and the frequency and severity of PWD agitation, thus providing proof-of-concept for BESI's potential to improve dyad outcomes and motivating a larger-scale followup study to establish proof-of-practice.

    Other: Intervention with Home-Based Caregivers

Interventions

  • OtherIntervention with Home-Based Caregivers

    We will assess whether real-time notifications of potential agitation via a wearable wrist device improves caregiver self-efficacy.

    Also known as: Real-time caregiver notifications

06

What researchers measure

Primary outcomes

  1. Improved Caregiver Self-Efficacy

    Increased scores on Revised Scale for Caregiver Self-Efficacy

    Time frame: 30 days

  2. Decreased Caregiver Burden

    Zarit Burden Interview score lowered

    Time frame: 30 days

07

Study locations

1 of 1 sites recruiting
  • University of Virginia
    Charlottesville, Virginia 22904, United States
    Recruiting
    • John Lach, Ph.D · Contactjlach@virginia.edu
    • Tonya Smith-Jackson, Ph.D · Contacttlsmithj@ncat.edu
    • Azziza Bankole, M.D. · Principal investigator
    • Martha Anderson, DNP · Sub investigator
08

References and documents

Publications

  • Alzheimer's Association. 2016 Alzheimer's disease facts and figures. Alzheimers Dement. 2016 Apr;12(4):459-509. doi: 10.1016/j.jalz.2016.03.001. PubMed 27570871 ↗
  • Friedman EM, Shih RA, Langa KM, Hurd MD. US Prevalence And Predictors Of Informal Caregiving For Dementia. Health Aff (Millwood). 2015 Oct;34(10):1637-41. doi: 10.1377/hlthaff.2015.0510. Erratum In: Health Aff (Millwood). 2015 Nov;34(11):2006. PubMed 26438738 ↗
  • Cohen-Mansfield J, Billig N. Agitated behaviors in the elderly. I. A conceptual review. J Am Geriatr Soc. 1986 Oct;34(10):711-21. doi: 10.1111/j.1532-5415.1986.tb04302.x. PubMed 3531296 ↗
  • Cummings J, Mintzer J, Brodaty H, Sano M, Banerjee S, Devanand DP, Gauthier S, Howard R, Lanctot K, Lyketsos CG, Peskind E, Porsteinsson AP, Reich E, Sampaio C, Steffens D, Wortmann M, Zhong K; International Psychogeriatric Association. Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. Int Psychogeriatr. 2015 Jan;27(1):7-17. doi: 10.1017/S1041610214001963. Epub 2014 Oct 14. PubMed 25311499 ↗
  • Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. J Gerontol. 1989 May;44(3):M77-84. doi: 10.1093/geronj/44.3.m77. PubMed 2715584 ↗
  • Colombo M, Vitali S, Cairati M, Vaccaro R, Andreoni G, Guaita A. Behavioral and psychotic symptoms of dementia (BPSD) improvements in a special care unit: a factor analysis. Arch Gerontol Geriatr. 2007;44 Suppl 1:113-20. doi: 10.1016/j.archger.2007.01.017. PubMed 17317443 ↗
  • Steinberg M, Shao H, Zandi P, Lyketsos CG, Welsh-Bohmer KA, Norton MC, Breitner JC, Steffens DC, Tschanz JT; Cache County Investigators. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2008 Feb;23(2):170-7. doi: 10.1002/gps.1858. PubMed 17607801 ↗
  • Sansoni J, Anderson KH, Varona LM, Varela G. Caregivers of Alzheimer's patients and factors influencing institutionalization of loved ones: some considerations on existing literature. Ann Ig. 2013 May-Jun;25(3):235-46. doi: 10.7416/ai.2013.1926. PubMed 23598807 ↗
  • Fonareva I, Oken BS. Physiological and functional consequences of caregiving for relatives with dementia. Int Psychogeriatr. 2014 May;26(5):725-47. doi: 10.1017/S1041610214000039. Epub 2014 Feb 10. PubMed 24507463 ↗
  • Mausbach BT, Chattillion EA, Roepke SK, Patterson TL, Grant I. A comparison of psychosocial outcomes in elderly Alzheimer caregivers and noncaregivers. Am J Geriatr Psychiatry. 2013 Jan;21(1):5-13. doi: 10.1016/j.jagp.2012.10.001. Epub 2013 Jan 2. PubMed 23290198 ↗
  • Epstein-Lubow G, Gaudiano B, Darling E, Hinckley M, Tremont G, Kohn R, Marino LJ Jr, Salloway S, Grinnell R, Miller IW. Differences in depression severity in family caregivers of hospitalized individuals with dementia and family caregivers of outpatients with dementia. Am J Geriatr Psychiatry. 2012 Sep;20(9):815-9. doi: 10.1097/JGP.0b013e318235b62f. PubMed 21997604 ↗
  • Bankole A, Anderson M, Smith-Jackson T, Knight A, Oh K, Brantley J, Barth A, Lach J. Validation of noninvasive body sensor network technology in the detection of agitation in dementia. Am J Alzheimers Dis Other Demen. 2012 Aug;27(5):346-54. doi: 10.1177/1533317512452036. PubMed 22815084 ↗
  • Rowe M, Lane S, Phipps C. CareWatch: A Home Monitoring System for Use in Homes of Persons With Cognitive Impairment. Top Geriatr Rehabil. 2007 Jan 1;23(1):3-8. doi: 10.1097/00013614-200701000-00003. PubMed 20454554 ↗
  • Sacco G, Joumier V, Darmon N, Dechamps A, Derreumaux A, Lee JH, Piano J, Bordone N, Konig A, Teboul B, David R, Guerin O, Bremond F, Robert P. Detection of activities of daily living impairment in Alzheimer's disease and mild cognitive impairment using information and communication technology. Clin Interv Aging. 2012;7:539-49. doi: 10.2147/CIA.S36297. Epub 2012 Dec 4. PubMed 23271900 ↗
  • Perlman CM, Hirdes JP. The aggressive behavior scale: a new scale to measure aggression based on the minimum data set. J Am Geriatr Soc. 2008 Dec;56(12):2298-303. doi: 10.1111/j.1532-5415.2008.02048.x. PubMed 19093929 ↗
  • Hall GR, Gerdner LA, Zwygart-Stauffacher M, et al: Principles of nonpharmacological management: Caring for people with Alzheimer's disease using a conceptual model. Psychiatric Annals 1995; 25(7):432-440
  • Smith M, Gerdner LA, Hall GR, Buckwalter KC. History, development, and future of the progressively lowered stress threshold: a conceptual model for dementia care. J Am Geriatr Soc. 2004 Oct;52(10):1755-60. doi: 10.1111/j.1532-5415.2004.52473.x. PubMed 15450057 ↗
  • Gerdner LA, Buckwalter KC, Hall GR: Temporal patterning of agitation and stressors associated with agitation: Case profiles to illustrate the Progressively Lowered Stress Threshold model. Journal of the American Psychiatric Nurses Association 2005; 11(4):215-222
  • Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, Lopez OL, DeKosky ST. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. 2000 Spring;12(2):233-9. doi: 10.1176/jnp.12.2.233. PubMed 11001602 ↗
  • Sclan SG, Reisberg B. Functional assessment staging (FAST) in Alzheimer's disease: reliability, validity, and ordinality. Int Psychogeriatr. 1992;4 Suppl 1:55-69. doi: 10.1017/s1041610292001157. PubMed 1504288 ↗
  • Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry. 1987 Aug;48(8):314-8. PubMed 3611032 ↗
  • Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993 Nov;43(11):2412-4. doi: 10.1212/wnl.43.11.2412-a. No abstract available. PubMed 8232972 ↗
  • Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell Scale for Depression in Dementia. Biol Psychiatry. 1988 Feb 1;23(3):271-84. doi: 10.1016/0006-3223(88)90038-8. PubMed 3337862 ↗
  • Orme JG, Reis J, Herz EJ. Factorial and discriminant validity of the Center for Epidemiological Studies Depression (CES-D) scale. J Clin Psychol. 1986 Jan;42(1):28-33. doi: 10.1002/1097-4679(198601)42:13.0.co;2-t. PubMed 3950011 ↗
  • Steffen AM, McKibbin C, Zeiss AM, Gallagher-Thompson D, Bandura A. The revised scale for caregiving self-efficacy: reliability and validity studies. J Gerontol B Psychol Sci Soc Sci. 2002 Jan;57(1):P74-86. doi: 10.1093/geronb/57.1.p74. PubMed 11773226 ↗
  • Bedard M, Molloy DW, Squire L, Dubois S, Lever JA, O'Donnell M. The Zarit Burden Interview: a new short version and screening version. Gerontologist. 2001 Oct;41(5):652-7. doi: 10.1093/geront/41.5.652. PubMed 11574710 ↗
  • MAHONEY FI, BARTHEL DW. FUNCTIONAL EVALUATION: THE BARTHEL INDEX. Md State Med J. 1965 Feb;14:61-5. No abstract available. PubMed 14258950 ↗
  • Duffy L, Gajree S, Langhorne P, Stott DJ, Quinn TJ. Reliability (inter-rater agreement) of the Barthel Index for assessment of stroke survivors: systematic review and meta-analysis. Stroke. 2013 Feb;44(2):462-8. doi: 10.1161/STROKEAHA.112.678615. Epub 2013 Jan 8. PubMed 23299497 ↗
  • Logsdon RG, Gibbons LE, McCurry, et al: Quality of life in Alzheimer's disease: Patient and caregiver reports. Journal of Mental Health and Ageing 1999; 5:21-32
  • Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4. PubMed 2748771 ↗
  • Grissom RJ. Heterogeneity of variance in clinical data. J Consult Clin Psychol. 2000 Feb;68(1):155-65. doi: 10.1037//0022-006x.68.1.155. PubMed 10710850 ↗
  • Jeste DV, Palmer BW, Appelbaum PS, Golshan S, Glorioso D, Dunn LB, Kim K, Meeks T, Kraemer HC. A new brief instrument for assessing decisional capacity for clinical research. Arch Gen Psychiatry. 2007 Aug;64(8):966-74. doi: 10.1001/archpsyc.64.8.966. PubMed 17679641 ↗
  • Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM. Monetary costs of dementia in the United States. N Engl J Med. 2013 Apr 4;368(14):1326-34. doi: 10.1056/NEJMsa1204629. PubMed 23550670 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 29, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03297268
Collaborators
Carilion Clinic, North Carolina Agriculture & Technical State University
Responsible party
Sponsor
First posted
Sep 29, 2017
Start date
May 2016
Primary completion
Aug 2019 (estimated)
Completion
Aug 2019 (estimated)
Last update
Sep 29, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion